Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer

Current Opinion in Pharmacology

Volumn 31, Issue , 2016, Pages 90-96

  Zahid, Heba ^a,b,c   Simpson, Evan R ^a,c   Brown, Kristy A ^a,c  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b TAIBAH UNIVERSITY   (Saudi Arabia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN; PIOGLITAZONE; PROTEIN KINASE LKB1; PROTEIN P53;

ADIPOCYTE; ANTINEOPLASTIC ACTIVITY; BODY MASS; BREAST CANCER; CALORIC RESTRICTION; CANCER RISK; CELL DEATH; CELL METABOLISM; CHRONIC INFLAMMATION; DIET; DRUG EFFECT; ENZYME REGULATION; ESTROGEN SYNTHESIS; EXERCISE; HUMAN; INFLAMMATION; INTRAPERITONEAL FAT; LIFESTYLE MODIFICATION; LIPID STORAGE; MACROPHAGE; MASTITIS; METABOLIC REGULATION; NONHUMAN; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; THERAPY EFFECT; WEIGHT REDUCTION; ADIPOSE TISSUE; ANIMAL; BREAST NEOPLASMS; COMPLICATION; FEMALE; LIPID METABOLISM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; AROMATASE; BREAST NEOPLASMS; CELL DEATH; ESTROGENS; FEMALE; HUMANS; INFLAMMATION; LIPID METABOLISM; OBESITY;

EID: 84996946601     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.11.003     Document Type: Review

References (66)

1. 1 Rutkowski, J.M., Stern, J.H., Scherer, P.E., The cell biology of fat expansion. J Cell Biol 208 (2015), 501–512.
2. 2 Obesity and Overweight. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/.
3. 3 Kelesidis, I., Kelesidis, T., Mantzoros, C.S., Adiponectin and cancer: a systematic review. Br J Cancer 94 (2006), 1221–1225.
4. 4• Keum, N., Greenwood, D.C., Lee, D.H., Kim, R., Aune, D., Ju, W., Adult weight gain and adiposity-related cancers: a dose–response meta-analysis of prospective observational studies. J Natl Cancer Inst, 2015, 107 The authors performed a meta-analysis on 50 observational studies investigating the relationship between adult weight gain and the risk of obesity-related cancers, including breast cancer. For each 5 kg increase in adult weight, the relative risk was 1.11 (95% CI = 1.08–1.13) for postmenopausal breast cancer among no or low hormone replacement therapy (HRT) users. Adult weight gain was not associated with increased breast cancer risk in premenopausal or postmenopausal women on HRT.
5. 5 Chen, G.C., Chen, S.J., Zhang, R., Hidayat, K., Qin, J.B., Zhang, Y.S., Qin, L.Q., Central obesity and risks of pre- and postmenopausal breast cancer: a dose–response meta-analysis of prospective studies. Obes Rev, 2016.
6. 6 Breast Cancer. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf.
7. 7 Brown, K.A., Simpson, E.R., Obesity and breast cancer: mechanisms and therapeutic implications. Front Biosci 4 (2012), 2515–2524.
8. 8 Xia, X., Chen, W., Li, J., Chen, X., Rui, R., Liu, C., Sun, Y., Liu, L., Gong, J., Yuan, P., Body mass index and risk of breast cancer: a nonlinear dose-response meta-analysis of prospective studies. Sci Rep, 4, 2014, 7480.
9. 9 Dobbins, M., Decorby, K., Choi, B.C.K., The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011. ISRN Preventive Medicine 2013. 2013, 16.
10. 10 Munsell, M.F., Sprague, B.L., Berry, D.A., Chisholm, G., Trentham-Dietz, A., Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 36 (2014), 114–136.
11. 11 Nechuta, S., Chen, W.Y., Cai, H., Poole, E.M., Kwan, M.L., Flatt, S.W., Patterson, R.E., Pierce, J.P., Caan, B.J., Ou Shu, X., A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer 138 (2016), 2088–2097.
12. 12• Robinson, P.J., Bell, R.J., Davis, S.R., Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer. Maturitas 79 (2014), 279–286 Five-year follow up with 1155 Australian women with ER+/PR+/HER2− breast cancer revealed that obesity was associated with an independent increased likelihood of breast cancer recurrence and metastasis.
13. 13 Jeon, Y.W., Kang, S.H., Park, M.H., Lim, W., Cho, S.H., Suh, Y.J., Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer, 15, 2015, 865.
14. 14 Cheraghi, Z., Poorolajal, J., Hashem, T., Esmailnasab, N., Doosti Irani, A., Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS ONE, 7, 2012, e51446.
15. 15 Yanai, A., Miyagawa, Y., Murase, K., Imamura, M., Yagi, T., Ichii, S., Takatsuka, Y., Ito, T., Hirota, S., Sasa, M., et al. Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. Int J Clin Oncol 19 (2014), 467–472.
16. 16 Santa-Maria, C.A., Yan, J., Xie, X.-J., Euhus, D.M., Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index. Int J Clin Oncol 20 (2015), 317–323.
17. 17 Protani, M., Coory, M., Martin, J.H., Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123 (2010), 627–635.
18. 18 Taghizadeh, N., Boezen, H.M., Schouten, J.P., Schroder, C.P., Elisabeth de Vries, E.G., Vonk, J.M., BMI and lifetime changes in BMI and cancer mortality risk. PLOS ONE, 10, 2015, e0125261.
19. 19•• Lee, Y.S., Kim, J.-W., Osborne, O., Oh, D.Y., Sasik, R., Schenk, S., Chen, A., Chung, H., Murphy, A., Watkins, S.M., et al. Increased adipocyte O(2) consumption triggers HIF-1α causing inflammation and insulin resistance in obesity. Cell 157 (2014), 1339–1352 In mouse models, high fat diet (HFD) leads to an increase in oxygen consumption which triggers HIF-1α resulting in the induction of adipose tissue inflammation. Genetic deletion of adipocyte HIF-1α protects from HFD-induced adipose tissue inflammation.
20. 20 Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K.-I., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest, 116, 2006, 1494.
21. 21 Lumeng, C.N., Bodzin, J.L., Saltiel, A.R., Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117 (2007), 175–184.
22. 22 Kihira, Y., Miyake, M., Hirata, M., Hoshina, Y., Kato, K., Shirakawa, H., Sakaue, H., Yamano, N., Izawa-Ishizawa, Y., Ishizawa, K., et al. Deletion of hypoxia-inducible factor-1α in adipocytes enhances glucagon-like peptide-1 secretion and reduces adipose tissue inflammation. PLOS ONE, 9, 2014, e93856.
23. 23 Matarese, G., Moschos, S., Mantzoros, C.S., Leptin in immunology. J Immunol (Baltim, MD: 1950) 174 (2005), 3137–3142.
24. 24 Subbaramaiah, K., Howe, L.R., Bhardwaj, P., Du, B., Gravaghi, C., Yantiss, R.K., Zhou, X.K., Blaho, V.A., Hla, T., Yang, P., et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 4 (2011), 329–346.
25. 25 Morris, P.G., Hudis, C.A., Giri, D., Morrow, M., Falcone, D.J., Zhou, X.K., Du, B., Brogi, E., Crawford, C.B., Kopelovich, L., et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 4 (2011), 1021–1029.
26. 26•• Iyengar, N.M., Morris, P.G., Zhou, X.K., Gucalp, A., Giri, D., Harbus, M.D., Falcone, D.J., Krasne, M.D., Vahdat, L.T., Subbaramaiah, K., et al. Menopause is a determinant of breast adipose inflammation. Cancer Prev Res (Phila) 8 (2015), 349–358 The authors demonstrated that white adipose tissue inflammation (WATi) in 237 women is increased in postmenopausal women independent of BMI.
27. 27 Subbaramaiah, K., Morris, P.G., Zhou, X.K., Morrow, M., Du, B., Giri, D., Kopelovich, L., Hudis, C.A., Dannenberg, A.J., Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2 (2012), 356–365.
28. 28 Purohit, A., Ghilchik, M.W., Duncan, L., Wang, D.Y., Singh, A., Walker, M.M., Reed, M.J., Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metabol 80 (1995), 3052–3058.
29. 29 Crichton, M.B., Nichols, J.E., Zhao, Y., Bulun, S.E., Simpson, E.R., Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. Mol Cell Endocrinol 118 (1996), 215–220.
30. 30 Zhao, Y., Agarwal, V.R., Mendelson, C.R., Simpson, E.R., Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. J Steroid Biochem Mol Biol 61 (1997), 203–210.
31. 31•• Brown, K.A., Simpson, E.R., Obesity and Breast Cancer: The Role of Dysregulated Estrogen Metabolism. 2014, Springer, New York Comperhensive review of the relationship between obesity and breast cancer. In particular, the role of dysregulated estrogen metabolism in the breast and molecular mechanisms involved.
32. 32 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
33. 33 Brown, K.A., Samarajeewa, N.U., Simpson, E.R., Endocrine-related cancers and the role of AMPK. Mol Cell Endocrinol 366 (2013), 170–179.
34. 34 Samarajeewa, N.U., Docanto, M.M., Simpson, E.R., Brown, K.A., CREB-regulated transcription co-activator family stimulates promoter II-driven aromatase expression in preadipocytes. Horm Cancer 4 (2013), 233–241.
35. 35 Wang, X., Simpson, E.R., Brown, K.A., p53: protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res, 76, 2016, 1668.
36. 36 Samarajeewa, N.U., Yang, F., Docanto, M.M., Sakurai, M., McNamara, K.M., Sasano, H., Fox, S.B., Simpson, E.R., Brown, K.A., HIF-1alpha stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Res, 15, 2013, R30.
37. 37 Subbaramaiah, K., Brown, K.A., Zahid, H., Balmus, G., Weiss, R.S., Herbert, B.S., Dannenberg, A.J., Hsp90 and PKM2 drive the expression of aromatase in Li–Fraumeni syndrome breast adipose stromal cells. J Biol Chem 291 (2016), 16011–16023.
38. 38•• Wang, X., Docanto, M.M., Sasano, H., Cancer KCFCfRiFB, Lo, C., Simpson, E.R., Brown, K.A., Prostaglandin E2 inhibits p53 in human breast adipose stromal cells: a novel mechanism for the regulation of aromatase in obesity and breast cancer. Cancer Res, 2015 Using human breast adipose stromal cells, the authors demonstrated that p53 is a repressor of aromatase expression and is negatively regulated by PGE2. It therefore demonstrates a novel tumor-suppressor role for p53. In Li–Fraumeni patients who have a germline mutation in TP53, aromatase is increased in ASCs, providing a rationale for the increased risk of estrogen-dependent breast tumors in these women.
39. 39 Eliassen, A.H., Colditz, G.A., Rosner, B., Willett, W.C., Hankinson, S.E., Adult weight change and risk of postmenopausal breast cancer. JAMA 296 (2006), 193–201.
40. 40 Prentice, R.L., Caan, B., Chlebowski, R.T., Patterson, R., Kuller, L.H., Ockene, J.K., Margolis, K.L., Limacher, M.C., Manson, J.E., Parker, L.M., et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (2006), 629–642.
41. 41 Chlebowski, R.T., Blackburn, G.L., Thomson, C.A., Nixon, D.W., Shapiro, A., Hoy, M.K., Goodman, M.T., Giuliano, A.E., Karanja, N., McAndrew, P., et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 98 (2006), 1767–1776.
42. 42 Scott, E., Daley, A.J., Doll, H., Woodroofe, N., Coleman, R.E., Mutrie, N., Crank, H., Powers, H.J., Saxton, J.M., Effects of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis after early-stage breast cancer: a randomized controlled trial. Cancer Causes Control 24 (2013), 181–191.
43. 43 Swisher, A.K., Abraham, J., Bonner, D., Gilleland, D., Hobbs, G., Kurian, S., Yanosik, M.A., Vona-Davis, L., Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile. Support Care Cancer 23 (2015), 2995–3003.
44. 44 Campbell, K.L., Foster-Schubert, K.E., Alfano, C.M., Wang, C.C., Wang, C.Y., Duggan, C.R., Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J Clin Oncol, 2012, 30.
45. 45 McTiernan, A., Tworoger, S.S., Ulrich, C.M., Yasui, Y., Irwin, M.L., Rajan, K.B., Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res, 2004, 64.
46. 46• Ennour-Idrissi, K., Maunsell, E., Diorio, C., Effect of physical activity on sex hormones in women: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res 17 (2015), 1–11 Data for circulating female sex hormones, including total and free estradiol, were extracted from 23 randomized controlled trials. Physical activity significantly reduced total and free estradiol levels, independent of menopausal status. Physical activity also decreased free testosterone, androstenedione, dehydroepiandrosterone-sulfate and adiposity markers. A significant increase in sex hormone-binding globulin (SHBG) was observed.
47. 47 Imayama, I., Ulrich, C.M., Alfano, C.M., Wang, C., Xiao, L., Wener, M.H., Campbell, K.L., Duggan, C., Foster-Schubert, K.E., Kong, A., et al. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 72 (2012), 2314–2326.
48. 48 Bhardwaj, P., Du, B., Zhou, X.K., Sue, E., Harbus, M.D., Falcone, D.J., Giri, D., Hudis, C.A., Kopelovich, L., Subbaramaiah, K., et al. Caloric restriction reverses obesity-induced mammary gland inflammation in mice. Cancer Prev Res (Phila) 6 (2013), 282–289.
49. 49 Libby, G., Donnelly, L.A., Donnan, P.T., Alessi, D.R., Morris, A.D., Evans, J.M., New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32 (2009), 1620–1625.
50. 50 Currie, C.J., Poole, C.D., Gale, E.A., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52 (2009), 1766–1777.
51. 51 Bodmer, M., Meier, C., Krahenbuhl, S., Jick, S.S., Meier, C.R., Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33 (2010), 1304–1308.
52. 52 Bosco, J.L., Antonsen, S., Sorensen, H.T., Pedersen, L., Lash, T.L., Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomark Prevent 20 (2011), 101–111.
53. 53 Ruiter, R., Visser, L.E., van Herk-Sukel, M.P., Coebergh, J.W., Haak, H.R., Geelhoed-Duijvestijn, P.H., Straus, S.M., Herings, R.M., Stricker, B.H., Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35 (2012), 119–124.
54. 54 Chlebowski, R.T., McTiernan, A., Wactawski-Wende, J., Manson, J.E., Aragaki, A.K., Rohan, T., Ipp, E., Kaklamani, V.G., Vitolins, M., Wallace, R., et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30 (2012), 2844–2852.
55. 55 Vissers, P.A., Cardwell, C.R., van de Poll-Franse, L.V., Young, I.S., Pouwer, F., Murray, L.J., The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. Breast Cancer Res Treat 150 (2015), 427–437.
56. 56 Dowling, R.J., Niraula, S., Chang, M.C., Done, S.J., Ennis, M., McCready, D.R., Leong, W.L., Escallon, J.M., Reedijk, M., Goodwin, P.J., et al. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res, 17, 2015, 32.
57. 57 Zhao, W., Li, A., Feng, X., Hou, T., Liu, K., Liu, B., Zhang, N., Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell Signal 28 (2016), 1401–1411.
58. 58 Frendo-Cumbo, S., MacPherson, R.E., Wright, D.C., Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance. Physiol Rep, 4, 2016.
59. 59 Lu, C.H., Hung, Y.J., Hsieh, P.S., Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. Eur J Pharmacol 789 (2016), 60–67.
60. 60 Zulian, A., Cancello, R., Girola, A., Gilardini, L., Alberti, L., Croci, M., Micheletto, G., Danelli, P., Invitti, C., In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts 4 (2011), 27–33.
61. 61 Brown, K.A., Hunger, N.I., Docanto, M., Simpson, E.R., Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 123 (2010), 591–596.
62. 62 Samarajeewa, N.U., Ham, S., Yang, F., Simpson, E.R., Brown, K.A., Promoter-specific effects of metformin on aromatase transcript expression. Steroids 76 (2011), 768–771.
63. 63 Hartemann-Heurtier, A., Halbron, M., Golmard, J.L., Jacqueminet, S., Bastard, J.P., Rouault, C., Ayed, A., Pieroni, L., Clement, K., Grimaldi, A., Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes Res Clin Pract 86 (2009), 37–43.
64. 64 Pfutzner, A., Schondorf, T., Tschope, D., Lobmann, R., Merke, J., Muller, J., Lehmann, U., Fuchs, W., Forst, T., PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 13 (2011), 637–643.
65. 65 Spencer, M., Yang, L., Adu, A., Finlin, B.S., Zhu, B., Shipp, L.R., Rasouli, N., Peterson, C.A., Kern, P.A., Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity. PLOS ONE, 9, 2014, e102190.
66. 66 Subbaramaiah, K., Howe, L.R., Zhou, X.K., Yang, P., Hudis, C.A., Kopelovich, L., Dannenberg, A.J., Pioglitazone, a PPARgamma agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1. Cancer Prev Res (Phila) 5 (2012), 1183–1194.